Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation

AbstractObjectiveTo study lipiodol deposition in portal vein tumour thrombus (PVTT) in predicting the treatment outcome of hepatocellular carcinoma (HCC) patients after transarterial chemoembolisation (TACE).MethodsWe retrospectively reviewed data from 379 HCC patients with PVTT who underwent TACE as the initial treatment at Sun Yat-Sen University Cancer Center from January 2008 to December 2015. Patients were grouped by positive and negative lipiodol deposition based on the extent of lipiodol deposition in PVTT. The overall survival (OS) and progression-free survival (PFS) were compared between negative and positive lipiodol deposition groups; furthermore, the value of the combinatorial evaluation of tumour responses and lipiodol deposition in PVTT in predicting prognosis was analysed in subgroup patients with stable disease (SD) after TACE.ResultsOf the 379 patients, 264 (69.7%) had negative and 115 (30.3%) had positive lipiodol deposition in PVTT after TACE. Multivariate analysis identified positive lipiodol deposition in PVTT as an independent prognostic factor for favourable OS (p = 0.001). The median OS and PFS of negative and positive lipiodol deposition groups were 4.70 vs. 8.97 months (p = 0.001) and 3.1 months vs. 5.8 months (p 
Source: European Radiology - Category: Radiology Source Type: research

Related Links:

Hepatocellular carcinoma (HCC) is the major type of primary liver cancer. Intrahepatic metastasis, such as portal vein tumor thrombosis (PVTT), strongly indicates poor prognosis of HCC. But now, there are limi...
Source: BMC Medical Genomics - Category: Genetics & Stem Cells Authors: Tags: Research article Source Type: research
Conclusions: The results obtained from these 5 cases demonstrate impressive tumor control from the combination of SBRT and checkpoint inhibitors in patients with large tumors of advanced HCC. Further prospective trials are warranted.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractExtension of tumor tissue within a vein is a recognized prognostic factor in abdominal malignancy because of its influence on tumor staging and selection of therapeutic management. With the advent of newer surgical techniques, and variable treatment strategies, imaging plays a crucial role in categorizing patients according to the tumor resectability and vascular reconstruction techniques during surgery. Understanding the clinical impact of tumor thrombus increases the awareness of the radiologist about the key findings in tumor staging and decision-making of surgical approach. Ultrasound (US), computed tomography ...
Source: Abdominal Imaging - Category: Radiology Source Type: research
Publication date: Available online 24 October 2019Source: Journal of Vascular and Interventional RadiologyAuthor(s): Jeffrey C. Cruz, Jennifer M. Watchmaker, Matthias M. Albin, Li Wang, Gong Wu, Jennifer C. Baker, Micah R. Fritsche, Sophoclis P. Alexopoulos, Lea Matsuoka, Jacob W. Fleming, James Su, Anthony J. Borgmann, Filip Banovac, Daniel B. BrownAbstractPurposeTo demonstrate that patients with hepatocellular carcinoma (HCC) and elevated baseline neutrophil/lymphocyte ratio (NLR) have a significantly greater risk of progressive disease following initial transarterial chemoembolization.Materials and MethodsA total of 190...
Source: Journal of Vascular and Interventional Radiology - Category: Radiology Source Type: research
ConclusionsCompared with surgical resection alone, postoperative adjuvant PVC treatment boosts survival and reduces early tumor recurrences in patients surgically treated for HCC and PVTT.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Portal vein tumor thrombosis (PVTT) is a common phenomenon in advanced stage hepatocellular carcinoma (HCC), with a prevalence rate ranging from 10% to 60% [1]. Patients with HCC and PVTT have a dismal prognosis, with an expected survival of 2 –4 months with the best supportive care [2]. Systemic therapy with Sorafenib is the current standard treatment, recommended by the Barcelona Clinic Liver Cancer (BCLC) staging system [3,4], although, survival benefit following Sorafenib administration is modest, with a median survival time of 5. 6–8.1 months [5,6].
Source: Physica Medica: European Journal of Medical Physics - Category: General Medicine Authors: Tags: Original paper Source Type: research
Abstract Objective: The blood of cancer patients is in a state of hypercoagulability, easily leading to thrombosis. Anemia is also a complication of tumors. Anemia and thrombosis affect the treatment of tumor patients. Methods: Ginsenosides Rb were extracted from the stems and leaves of American ginseng using water-saturated ethanol and ethyl acetate in silica gel column. Tumor mice model was established by injecting H22 hepatocellular carcinoma cells into the axilla of mice. Mice were randomly divided into 6 groups: normal control group, model control group, positive control group, low dose group (7 mg/kg), ...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
In this study, 639 patients received TACE plus RT for HCC with MVI as a first-line treatment between January 2010 and December 2015. RESULTS: Main/bilateral portal vein and/or inferior vena cava tumor thrombus was observed in 353 (55.2%) patients. The median radiation dose was 39 Gy (range 24-50) with a 2.5-Gy (2-5) median fraction size. The median overall survival was 10.7 months, with 1- and 2-year survival rates of 46.5% and 23.9%, respectively. In the multivariate analysis, Child-Pugh classification B, tumor size>10 cm, infiltrative/diffuse type, presence of extrahepatic metastasis, alpha-fetoprotein>1...
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
CONCLUSIONS lncRNA-D16366 was decreased in HCC, and might be an independent diagnostic and prognostic indicator in the disease. PMID: 31475695 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Neoadjuvant three-dimensional conformal radiotherapy (RT) followed by hepatectomy boosts outcomes over those with hepatectomy alone in patients with resectable hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT), researchers from China report.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver Cancer | Radiology | Study | Thrombosis